The current goal of insulin therapy in type 1 diabetes is to reach >70% of time in the target glucose range while minimising the burden of hypoglycaemia, together with decreasing the risk of development of long-term diabetes-related complications [22]. This evidence concerns the gene INS and type 1 diabetes mellitus.